Skip to main content

Baxter International Value Stock - Dividend - Research Selection

Baxter International

ISIN: US0718131099, WKN: 853815

Market price date: 06.07.2022
Market price: 65,11 USD

Baxter International Fundamental data and company key figures of the share

Annual reports in USD
Key figures 06-03-2022
Cash flow
Net operating cash flow
Capital Expenditures -743.000.000
Free cash flow 1.479.000.064
Balance sheet
Total Equity
Liabilities & Shareholders equity 33.521.000.000
Income statement
Net income
Eps (diluted) 2,530
Diluted shares outstanding 506.000.000
Net sales/revenue 12.784.000.000

Fundamental ratios calculated on: 06-07-2022

Key figures 06-07-2022
Cash flow
P/C 14,83
P/FC 22,28
Balance sheet
Income statement
Div. Yield1,66%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization32.945.659.904,00 USD
CountryUnited States
IndicesMSCI World Index,S&P 500
SectorsHealth Care Equipment
Raw Data SourceUS GAAP in Millionen USD
Stock Split2015-07-01,1841.0000/1000.0000; 2001-05-31,2.0000/1.0000; 1992-12-01,100000.0000/90823.0000; 1983-11-18,2.0000/1.0000; 1981-11-09,1.0000/2.0000; 1981-11-04,2.0000/1.0000

Description of the company

Baxter International Inc. (Baxter,) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company operated in two segments: BioScience and Medication Delivery. It is engaged in the medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures products in 27 countries and sells the products in more than 100 countries. In September 2013, Baxter International Inc completed the acquisition of Gambro AB.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio

Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.

'Minions: The Rise of Gru' tops $108 million as parents flock back to cinemas, kids in tow

"Minions: The Rise of Gru" generated more than $108 million in ticket sales during its domestic opening weekend.

10 Best Stocks to Buy Now According to Billionaire Larry Robbins

In this article, we discuss the 10 best stocks to buy now according to billionaire Larry Robbins. You can skip our detailed analysis of Glenview Capital and go directly to 5 Best Stocks to Buy Now According to Billionaire Larry Robbins. Larry Robbins is a billionaire hedge fund manager as well as a philanthropist. He […]

Interesting BAX Put And Call Options For August 12th

Staff article entitled Interesting BAX Put And Call Options For August 12th, about stock options, from Stock Options Channel.

Starz could turn into an 'acquisition machine' after Lionsgate spins it off

A publicly traded Starz may look to increase in size by targeting other subscale media and entertainment companies.

Movies have momentum headed into the second half of 2022, if inflation doesn't spoil it

A string of solid theatrical performances coupled with a strong slate of upcoming films has left most box office analysts optimistic.

Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.


Baxter International Inc. (NYSE: BAX), a global medtech leader, today released its 2021 Corporate Responsibility Report, demonstrating how the company is progressing toward its 2030 Corporate Responsibility Commitment and Goals. The report highlights the continued progress Baxter has made to advance environmental, social and governance (ESG) performance across its operations and philanthropic programs.

Baxter releases 2021 Corporate Responsibility Report

Baxter International rele... BAX

Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Baxter International (BAX)

There&#8217;s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dexcom (<span class='tr-stock-ticker' style='color:blue; font-w...